431 related articles for article (PubMed ID: 27113167)
1. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
[TBL] [Abstract][Full Text] [Related]
2. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Wang Y; Liu C; Zhang L; Xia Q; Zhang Y; Wu J; Jiang C; Chen Y; Wu Y; Zha X; Yu X; Kong W
Cancer Immunol Immunother; 2012 Oct; 61(10):1857-67. PubMed ID: 22706381
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
[TBL] [Abstract][Full Text] [Related]
4. MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model.
Liu C; Xie Y; Sun B; Geng F; Zhang F; Guo Q; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H
Scand J Immunol; 2018 Feb; 87(2):63-72. PubMed ID: 29193199
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model.
Wang YQ; Zhang HH; Liu CL; Wu H; Wang P; Xia Q; Zhang LX; Li B; Wu JX; Yu B; Gu TJ; Yu XH; Kong W
Int Immunopharmacol; 2013 Sep; 17(1):9-17. PubMed ID: 23624214
[TBL] [Abstract][Full Text] [Related]
6. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis.
Yin X; Wang W; Zhu X; Wang Y; Wu S; Wang Z; Wang L; Du Z; Gao J; Yu J
Biochem Biophys Res Commun; 2015 Sep; 465(2):239-44. PubMed ID: 26253468
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice.
Xia Q; Geng F; Zhang FF; Liu CL; Xu P; Lu ZZ; Zhang HH; Kong W; Yu XH
Vaccine; 2016 Aug; 34(38):4526-4535. PubMed ID: 27498213
[TBL] [Abstract][Full Text] [Related]
9. Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect.
Liu C; Lu Z; Xie Y; Guo Q; Geng F; Sun B; Wu H; Yu B; Wu J; Zhang H; Yu X; Kong W
Immunol Lett; 2018 Aug; 200():33-42. PubMed ID: 29894719
[TBL] [Abstract][Full Text] [Related]
10. A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene.
Choi DH; Woo JK; Choi Y; Seo HS; Kim CW
Mol Med Rep; 2011; 4(5):885-90. PubMed ID: 21725596
[TBL] [Abstract][Full Text] [Related]
11. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
13. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
[TBL] [Abstract][Full Text] [Related]
14. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.
Yang M; Yan Y; Fang M; Wan M; Wu X; Zhang X; Zhao T; Wei H; Song D; Wang L; Yu Y
Int Immunopharmacol; 2012 Aug; 13(4):408-16. PubMed ID: 22595192
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
[TBL] [Abstract][Full Text] [Related]
16. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
[TBL] [Abstract][Full Text] [Related]
18. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of anti-tumor effect of plasmid DNA-carrying MUC1 by the adjuvanticity of FLT3L in mouse model.
Gao FS; Zhan YT; Wang XD; Zhang C
Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):353-357. PubMed ID: 30111221
[TBL] [Abstract][Full Text] [Related]
20. MUC1 and maltose‑binding protein recombinant fusion protein combined with Bacillus Calmette‑Guerin induces MUC1‑specific and nonspecific anti‑tumor immunity in mice.
Fang F; Ma J; Ni W; Wang F; Sun X; Li Y; Li Q; Xie F; Wang J; Zhai R; Liu Z; Gao S; Tai G
Mol Med Rep; 2014 Aug; 10(2):1056-64. PubMed ID: 24912810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
